Leuconostoc mesenteroides CJLM119 strain and fermented composition for food containing the culture
A fermentation composition using Leuconostoc mesenteroides CJLM119 strain or its culture effectively enhances immune responses and improves intestinal health by fermenting foods like garlic and chili pepper powder, addressing the limitations of existing fermented foods in this regard.
Patent Information
- Application Number
- JP2024532374
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-31
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-11-29
AI Technical Summary
Existing fermented foods do not effectively enhance immunity and improve intestinal health, and there is a need for a fermentation composition that can enhance these benefits using Leuconostoc mesenteroides CJLM119 strain or its culture.
A fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or its culture, which is used to ferment foods such as garlic and chili pepper powder, enhancing immune responses and improving intestinal health by regulating bacterial flora and suppressing harmful bacteria.
The composition increases immune responses by increasing the expression of TNF-α and IL-6 and improves intestinal health by activating beneficial bacteria while suppressing harmful bacteria, thereby enhancing overall gut health and immune function.
Smart Images

Figure 2024541607000001_ABST
Abstract
Description
[Technical field]
[0001] The present application relates to a composition for enhancing immunity or improving intestinal health, which is fermented with a fermentation composition containing at least one selected from Leuconostoc mesenteroides CJLM119 strain or a culture thereof, and which contains at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom. [Background technology]
[0002] Fermented foods are foods and beverages whose ingredients have been transformed by the growth of specific microorganisms and the action of enzymes. It has been reported that beneficial bacteria, including lactic acid bacteria, transform the chemical components that make up food ingredients during the fermentation process, thereby increasing the bioavailability of nutrients, enhancing food safety as a biological preservative, decomposing toxic substances and nutritional inhibitors, and producing physiologically active substances (Non-Patent Document 1).
[0003] Among the lactic acid bacteria, Leuconostoc mesenteroides is known as a representative lactic acid bacterium involved in the lactic acid fermentation of vegetables, and is found in fermented vegetables such as kimchi. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] US Patent Application Publication No. 2019 / 0297908 [Non-patent literature]
[0005] [Non-Patent Document 1] Tamang JP, et al., Front Microbiol (2016), 7, 578. Summary of the Invention [Problem to be solved by the invention]
[0006] The present application provides a composition for enhancing immunity or improving intestinal health, which is fermented with a fermentation composition containing at least one selected from Leuconostoc mesenteroides CJLM119 strain or a culture thereof, and which contains at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom. [Means for solving the problem]
[0007] The present application aims to provide a composition for fermentation comprising at least one selected from the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0008] The present application also aims to provide an immune enhancing food composition comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0009] Furthermore, the present application aims to provide a food composition for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0010] Furthermore, the present application aims to provide a functional food for enhancing immunity, which contains a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0011] Furthermore, the present application aims to provide a functional food for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0012] Furthermore, the present application aims to provide a method for enhancing the immune enhancing effect of a composition, comprising a step of fermenting the composition with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0013] Furthermore, the present application aims to provide a method for enhancing the intestinal health improving effect of a composition, comprising a step of fermenting the composition with Leuconostoc mesenteroides CJLM119 strain or a culture thereof. Effect of the Invention
[0014] The compositions of the present application have immune enhancing and gut health improving effects. [Brief description of the drawings]
[0015] [Figure 1] FIG. 2 shows the results of treating J774A.1 cells, which are mouse immune cells, with the fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2, and then examining their cytotoxicity. [Diagram 2] This figure shows the results of treating mouse immune cells, J774A.1 cells, with fermentation compositions and their supernatants containing Leuconostoc mesenteroides CJLM119 strain at 5 x 106 cfu / mL (fermentation composition A), 106 cfu / mL (fermentation composition B), and 5 x 105 cfu / mL (fermentation composition C), and then confirming their cytotoxicity. [Diagram 3] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL and 6.25 x 106 cfu / mL, and then confirming the cytotoxicity. [Figure 4] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL, 2.5 x 106 cfu / mL, and 5.0 x 106 cfu / mL, and then confirming the cytotoxicity. [Diagram 5]FIG. 1 shows the results of analyzing the expression level of TNF-α (Tumor necrosis factor-α) in J774A.1 cells, which are mouse immune cells, treated with the fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2 (***p<0.001). [Figure 6] FIG. 1 shows the results of analyzing the expression level of IL-6 (Interleukin-6) in J774A.1 mouse immune cells treated with the fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2 (***p<0.001). [Figure 7] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain at 5 x 106 cfu / mL, 106 cfu / mL, and 5 x 105 cfu / mL, and then analyzing the TNF-α expression level (***p<0.001, **p<0.01). [Figure 8] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain at 5 x 106 cfu / mL, 106 cfu / mL, and 5 x 105 cfu / mL, and then analyzing the IL-6 expression level (***p<0.001, **p<0.01). [Figure 9] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL and 6.25 x 106 cfu / mL, and then analyzing the TNF-α expression level (***p<0.001, ##p<0.01, #p<0.05). [Figure 10] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL, 2.5 x 106 cfu / mL, and 5.0 x 106 cfu / mL, and then analyzing the TNF-α expression level (**p<0.01, *p<0.05). [Figure 11]This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL and 6.25 x 106 cfu / mL, and then analyzing the IL-6 expression level (***p<0.001, ##p<0.01, #p<0.05). [Figure 12] This figure shows the results of treating mouse immune cells, J774A.1 cells, with a fermentation composition containing Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain at 1.25 x 106 cfu / mL, 2.5 x 106 cfu / mL, and 5.0 x 106 cfu / mL, and then analyzing the IL-6 expression level (***p<0.001, **p<0.01, *p<0.05). [Figure 13] FIG. 1 is a graph comparing the harmful bacteria growth inhibitory effect of the fermentation composition of Production Example 4. Fermentation composition: Fermentation Supernatant of fermentation composition: Metabolite DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] These will be described in detail below. Each description and embodiment disclosed in this application is also applicable to other descriptions and embodiments. That is, all combinations of various elements disclosed in this application are included in this application. In addition, this application is not limited to the following specific description. Furthermore, many papers and patent documents are referenced throughout this specification, and citations are provided. The disclosure contents of the cited papers and patent documents are incorporated in their entirety into this specification by reference, thereby more clearly explaining the state of the art to which this application pertains and the contents of this application.
[0017] One aspect of the present application provides a composition for fermentation comprising at least one selected from Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0018] The strain of the present application may be a Leuconostoc sp. strain, specifically, Leuconostoc mesenteroides, and more specifically, Leuconostoc mesenteroides CJLM119 strain deposited under accession number KCTC13043BP (Patent Document 1).
[0019] In this application, the term "culture" refers to the entire medium containing the strain, its metabolites, extra nutrients, etc., obtained by culturing the strain of this application for a predetermined period of time in a medium that supplies nutrients so that the strain can grow or survive in a test tube. Also, a "culture" is a composition containing a strain, and in this application, a culture is used for the same purpose as a strain. In this application, the term "culture" is used interchangeably with "culture solution," "culture supernatant," "conditioned culture solution," or "conditioned medium."
[0020] In the present application, "culturing" means growing the microorganism under appropriately adjusted environmental conditions. The culturing process of the present application can be carried out in a suitable medium and under suitable culture conditions known in the art. Such a culturing process can be easily adjusted and used by a person skilled in the art depending on the strain selected. Specifically, the culturing can be batch, continuous, or fed-batch culture, but is not limited thereto.
[0021] Carbon sources contained in the medium include, but are not limited to, sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, cellulose, etc., fats and oils such as soybean oil, sunflower oil, castor oil, coconut oil, etc., fatty acids such as palmitic acid, stearic acid, linoleic acid, etc., alcohols such as glycerin, ethanol, etc., and organic acids such as acetic acid, etc. These substances can be used alone or in mixtures.
[0022] The nitrogen sources contained in the medium include organic nitrogen sources such as peptone, yeast extract, meat juice, malt extract, corn steep liquor, soybean meal, urea, etc., and inorganic nitrogen sources such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc. These nitrogen sources can be used alone or in combination, but are not limited to these.
[0023] Phosphorus sources included in the medium include, but are not limited to, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and their corresponding sodium-containing salts.
[0024] The medium may also contain metal salts such as magnesium sulfate, iron sulfate, etc., as well as amino acids, vitamins, suitable precursors, etc. These media or precursors may be added to the culture in a batch or continuous manner, but are not limited thereto.
[0025] The pH of the culture can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid to the culture in a suitable manner during the culture. Also, foam formation can be suppressed during the culture using an antifoaming agent such as fatty acid polyglycol ester. Furthermore, oxygen or oxygen-containing gas can be injected into the culture to maintain the aerobic state of the culture, and no gas can be injected, or nitrogen, hydrogen, or carbon dioxide gas can be injected to maintain the anaerobic and microaerobic states.
[0026] The culture can be obtained by culturing the strain of the present application at 10°C to 40°C for 6 to 48 hours, for example, at 20°C to 40°C for 12 to 36 hours, or at 30°C to 40°C for 16 to 24 hours.
[0027] The culture of the present application includes a viable bacterial culture (i.e., the result of culturing viable bacteria in a medium), a culture in which the viable bacteria in the viable bacterial culture have been killed, a culture filtrate (i.e., the result of removing either killed or viable bacteria from the culture), and a concentrate or lyophilized product thereof.
[0028] The culture filtrate can be obtained by leaving the culture solution to stand for a predetermined time and collecting only the upper liquid layer excluding the part that has sunk to the bottom layer, removing the bacterial cells by filtration, or centrifuging the culture solution to remove the precipitate at the bottom and collecting only the upper liquid. In this application, the "culture filtrate" is used interchangeably with the "supernatant".
[0029] The bacterial cells can be obtained by centrifuging the culture solution and collecting the part that sinks to the bottom, or by leaving the bacterial cells to stand for a predetermined period of time and removing the liquid above, since the bacterial cells sink to the bottom of the culture solution due to gravity.
[0030] The concentrate can be obtained by concentrating the culture medium of the strain itself, or by subjecting the culture medium to centrifugation or filtration and then concentrating the resulting supernatant.
[0031] The lyophilisate can be obtained from the culture medium of the strain itself or by lyophilising the culture medium.
[0032] The fermentation composition of the present application can be used in the production of various fermented foods, specifically, but not limited to, for fermenting condiments such as garlic, chili powder, seasonings, etc.
[0033] By fermenting with the fermentation composition of the present application, it is possible to produce foods having immune enhancing effects and / or intestinal health improving effects, but the present invention is not limited thereto.
[0034] Another aspect of the present application provides an immune enhancing food composition comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0035] Yet another aspect of the present application provides a food composition for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0036] The Leuconostoc mesenteroides CJLM119 strain and culture were as described above.
[0037] The food composition of the present application may include a fermented product fermented with the fermentation composition of the above-mentioned embodiment. For example, the fermented product includes a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof. Alternatively, the fermented product includes a fermented product obtained by further fermenting the fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0038] In one embodiment of the present application, the food composition of the present application may include garlic, chili powder, a nitrogen source, etc., fermented with the fermentation composition of the above-mentioned embodiment.
[0039] By "fermentation" in this application is meant any activity or process involving the enzymatic or metabolic breakdown of organic substances using microorganisms.
[0040] In the present application, the term "fermented product" refers to a product resulting from enzymatic or metabolic decomposition by fermentation using a microorganism. For example, the fermented product may be in a liquid state. The fermented product may also be a raw liquid or a supernatant thereof that is a result of fermentation.
[0041] In another embodiment of the present application, the fermentation product of the present application includes viable bacterial cells.
[0042] In still another embodiment of the present application, the fermented product of the present application may be further fermented. For example, the fermented product of the present application may be added to vegetables and the like and further fermented, or may be added to a liquid composition and further fermented. Examples of the vegetables include, but are not limited to, Chinese cabbage and Japanese radish.
[0043] The fermented product of the present application may be fermented with at least one selected from the strains of the present application or a culture thereof at 25° C. to 40° C. The fermentation of the present application may be fermented for 10 hours to 30 hours with at least one selected from the strains of the present application or a culture thereof.
[0044] For example, the fermentation temperature of the present application may be a range consisting of a lower limit selected from 25° C. or more, 27° C. or more, 28° C. or more, and 29° C. or more, and / or an upper limit selected from 40° C. or less, 35° C. or less, 33° C. or less, and 31° C. or less. The fermentation time of the present application may be a range consisting of a lower limit selected from 10 hours or more, 12 hours or more, 14 hours or more, 16 hours or more, and 18 hours or more, and / or an upper limit selected from 30 hours or less, 28 hours or less, 27 hours or less, 26 hours or less, and 25 hours or less.
[0045] The fermented product of the present application may be a product obtained by fermenting a composition comprising at least one selected from the group consisting of garlic, chili powder, and a nitrogen source. As an example, the composition to be fermented of the present application may be a composition comprising at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, but is not limited thereto. As another example, the fermented product of the present application may be a composition comprising at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, to which the strain of the present application and / or a culture thereof has been added and fermented.
[0046] The fermented product of the present application may be one which has been fermented by adding 0.5 to 4% by weight of the strain of the present application and / or a culture thereof to the total weight of a composition containing at least one selected from the group consisting of garlic, chili powder, and a nitrogen source.
[0047] For example, the strains and / or cultures thereof of the present application may be present in a range consisting of a lower limit selected from 1% by weight or more, 1.2% by weight or more, 1.6% by weight or more, and 1.8% by weight or more, and / or an upper limit selected from 3.5% by weight or less, 2.8% by weight or less, 2.6% by weight or less, and 2.2% by weight or less, based on the total weight of the composition.
[0048] The fermented product of the present application may be a composition containing 4 to 10% by weight of garlic based on the total weight of the composition, which is obtained by fermenting the composition. As an example, the composition to be fermented of the present application is a composition containing at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, but is not limited thereto. As another example, the composition to be fermented of the present application, which contains at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, may contain 4 to 10% by weight of garlic based on the total weight of the composition.
[0049] For example, the garlic may be present in a range consisting of a lower limit selected from 4 wt % or more, 5 wt % or more, 6 wt % or more, and 6.5 wt % or more, and / or an upper limit selected from 10 wt % or less, 9 wt % or less, 8 wt % or less, and 7.5 wt % or less, relative to the total weight of the composition.
[0050] The garlic is included in the composition of the present application in the form of minced garlic, extract, concentrate, powder, etc., but is not limited thereto, and any commercially available garlic, minced garlic products, or products processed into the form of extract, concentrate, powder, etc. may be used.
[0051] As yet another example, the composition to be fermented in the present application, which contains at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, may contain 0.5 to 4 wt. % chili powder relative to the total weight of the composition.
[0052] For example, the chili powder may be present in a range consisting of a lower limit selected from 0.5% by weight or more, 1% by weight or more, 1.2% by weight or more, 1.6% by weight or more, and 1.8% by weight or more, and / or an upper limit selected from 4% by weight or less, 3.5% by weight or less, 2.8% by weight or less, 2.6% by weight or less, and 2.2% by weight or less, relative to the total weight of the composition.
[0053] The chili powder may be prepared by drying and grinding chili peppers or by freeze-drying and powdering them, but is not limited thereto, and any commercially available chili powder may be used.
[0054] As yet another example, the composition to be fermented in the present application, which contains at least one selected from the group consisting of garlic, chili powder, and a nitrogen source, may contain 0.1 to 1.5 wt % of the nitrogen source relative to the total weight of the composition.
[0055] For example, the nitrogen source may be present in a range consisting of a lower limit selected from 0.3 wt. % or more, 0.6 wt. % or more, 0.9 wt. % or more, and 1.1 wt. % or more, and / or an upper limit selected from 1.45 wt. % or less, 1.4 wt. % or less, 1.35 wt. % or less, and 1.3 wt. % or less, based on the total weight of the composition.
[0056] The nitrogen source may be edible, for example, seasoning, such as TasteNrich® (CJ CheilJedang), but is not limited thereto.
[0057] In particular, the compositions of the present application may include garlic.
[0058] The fermented product of the present application may be a product obtained by fermenting a composition further comprising at least one selected from a carbon source or a salt.
[0059] As an example, the composition to be fermented in the present application may contain 2 to 4% by weight of a carbon source based on the total weight of the composition.
[0060] For example, the carbon source may be present in a range consisting of a lower limit selected from 2.2 wt % or more, 2.4 wt % or more, 2.6 wt % or more, and 2.8 wt % or more, and / or an upper limit selected from 3.8 wt % or less, 3.6 wt % or less, 3.4 wt % or less, and 3.2 wt % or less, relative to the total weight of the composition.
[0061] The carbon source may be edible. Examples of the carbon source include fructose, sucrose, glucose, etc., such as fructose, specifically crystalline fructose, but are not limited thereto.
[0062] As an example, the composition to be fermented in the present application may contain 0.1 to 2% by weight of salt based on the total weight of the composition.
[0063] For example, the salt may be present in a range consisting of a lower limit selected from 0.5% by weight or more, 0.8% by weight or more, 1% by weight or more, and 1.2% by weight or more, and / or an upper limit selected from 1.9% by weight or less, 1.8% by weight or less, 1.7% by weight or less, and 1.6% by weight or less, relative to the total weight of the composition.
[0064] The fermented product of the present application may be a fermented composition further comprising ginger.
[0065] As an example, the composition to be fermented in the present application may contain 0.1 to 1.5% by weight of ginger based on the total weight of the composition.
[0066] For example, the ginger may be present in a range consisting of a lower limit selected from 0.3 wt. % or more, 0.6 wt. % or more, 0.9 wt. % or more, and 1.1 wt. % or more, and / or an upper limit selected from 1.45 wt. % or less, 1.4 wt. % or less, 1.35 wt. % or less, and 1.3 wt. % or less, relative to the total weight of the composition.
[0067] The fermented product of the present application may be a product of fermenting a composition further comprising water.
[0068] In one embodiment of the present application, the water may be added by mixing all the raw materials contained in the composition to be fermented in the present application, and then adding water until the total weight of the composition becomes 100% by weight.
[0069] The fermentation product of the present application may contain at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom.
[0070] In the present application, the term "lysate" refers to a product obtained by disrupting the cell walls of the microorganisms contained in the culture solution or its concentrate by chemical or physical forces. In the present application, the term "lysate" is used interchangeably with "lysate".
[0071] In the present application, the term "extract" refers to a substance obtained by removing microorganisms from the culture medium or a concentrate thereof.
[0072] In addition, examples of components derived from the strains of the present application include metabolic substances derived from the strains, and cytoplasmic fractions obtained by disrupting the cells containing the metabolic substances derived from the strains, etc. In addition, the form of the strains suitable for inclusion in food compositions, methods for formulation, methods for separating components derived from the strains, etc. are well known to those skilled in the art.
[0073] In the above-mentioned embodiment of the present application, the fermented product of the present application may be fermented by including ingredients contained in kimchi base (kimchi seasoning).
[0074] The food composition of the present application may have an immune enhancing effect.
[0075] In the present application, "immune enhancement" refers to an effect of increasing immune responses by various specific or non-specific methods, and may further include an immunomodulatory effect. Examples of the immune enhancement effect include defense against external pathogens, removal of dead cells, and increased secretion of immune mediators by improving the activity of macrophages, and also include effects of improving the activity of immune regulators to improve the activity of the immune system, suppressing angiogenesis, and increasing the growth inhibitory power against pathogens, thereby preventing immune-related diseases.
[0076] Specifically, the immune enhancing effect may be obtained by increasing the secretion of immune mediators.
[0077] Examples of the immune mediator include Th1-type pro-inflammatory cytokines, such as TNF-α (Tumor necrosis factor-α), IL-6 (Interleukin-6), and IL-1β, but are not limited to these.
[0078] In one embodiment of the present application, the composition of the present application may increase the expression of TNF-α or IL-6.
[0079] The food composition of the present application may have a gut health improving effect.
[0080] In the present application, "improving intestinal health" refers to the effect of regulating the intestinal beneficial and harmful bacterial flora to maintain the intestinal environment in a normal state. Examples of the intestinal health improving effect include the effect of activating the intestinal beneficial bacterial flora and suppressing the harmful bacterial flora, the effect of strengthening the intestinal tight junction barrier function to improve and activate the overall intestinal function, the effect of increasing the content of short-chain fatty acids in the intestine, and the effect of inducing the proliferation of intestinal epithelial cells. In the present application, the "intestinal health improving effect" is used interchangeably with the "intestinal regulation effect".
[0081] Specifically, the intestinal health improving effect may be obtained by activating the intestinal beneficial bacteria flora and suppressing the harmful bacteria flora based on the harmful bacteria growth inhibiting effect.
[0082] The food composition of the present application may have the effect of inhibiting the growth of harmful bacteria.
[0083] The harmful bacteria may be a pathogenic microorganism.
[0084] The pathogenic microorganism is not particularly limited as long as it causes a specific disease upon infection, and examples thereof include Escherichia sp., Staphylococcus sp., Salmonella sp., Shigella sp., Klebsiella sp., Enterobacteriaceae sp., Pseudomonas sp., Moraxella sp., Helicobacter sp., Stenotrophomonas sp., Listeria sp., and Vibrio sp., and examples thereof include Escherichia coli, Staphylococcus aureus, and examples thereof include Escherichia coli, Staphylococcus aureus, and examples thereof include Staphylococcus aureus, ... aureus, Salmonella enteritidis, Salmonella typhi, Shigella dysenteriae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, Helicobacter pylori, Stenotrophomonas maltophilia, Listeria monocytogenes, Vibrio cholerae, Vibrio vulnificus, and more specifically, Escherichia coli or Staphylococcus aureus.
[0085] The food composition of the present application may include a fermented product fermented with the fermentation composition of the above-mentioned embodiment. For example, the fermented product includes a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof. Alternatively, the fermented product includes a fermented product obtained by further fermenting the fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof, as described above.
[0086] For example, the fermented product may be in a liquid state, or may be a raw liquid or a supernatant thereof that is a result of fermentation.
[0087] The fermented product may be one that has been further fermented. For example, the fermented product of the present application may be added to vegetables and the like and further fermented, or may be added to a liquid composition and further fermented. Examples of the vegetables include, but are not limited to, Chinese cabbage and Japanese radish.
[0088] When the fermentation product is a liquid fermentation product, the fermentation product of the present application includes the liquid fermentation product and / or a fermentation product obtained by further fermenting the liquid fermentation product. Here, the further fermentation product may be, but is not limited to, a liquid or solid fermentation product.
[0089] The food composition of the present application may be in the form of a food additive other than a food composition, but is not limited thereto.
[0090] The food composition of the present application may further contain a food additive, and unless otherwise specified, the suitability as a "food additive" is determined based on the specifications and standards for the item in question in accordance with the general provisions and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety.
[0091] Examples of items listed in the "Food Additives Code" include chemically synthesized products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon coloring, licorice extract, crystalline cellulose, and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents added to noodles, preservative preparations, and tar color preparations.
[0092] The food products of the present application include beverages such as fruit drinks, vegetable drinks, carbonated drinks, soy milk, lactobacillus drinks such as yogurt, mixed drinks, kimchi, kimchi base (kimchi seasoning), fermented foods, confectioneries such as bread, mochi, nuts, candies, chocolates, chewing gum, jams, ice cream products such as ice cream, frozen desserts, and ice cream powders, milk, low-fat milk, lactose-decomposed milk, processed milk, goat's milk, fermented milk, butter milk, concentrated milk, dairy cream, butter milk, natural Examples of suitable foods include, but are not limited to, dairy products such as cheese, processed cheese, milk powder, and whey; meat products such as processed meat products, processed eggs, and hamburgers; fish products such as kamaboko, ham, sausage, bacon, and processed fish products; noodles such as ramen, dried noodles, fresh noodles, oily noodles, gelatinized dried noodles, improved aged noodles, frozen noodles, and pasta; and seasonings such as soy sauce, miso, gochujang, sweet bean paste, cheonggukjang, mixed sauce, vinegar, sauces, tomato ketchup, curry, and dressings.
[0093] In addition, the food composition of the present application may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloids, thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. In addition, the food composition of the present application may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination.
[0094] Yet another aspect of the present application provides a functional food for enhancing immunity, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0095] Yet another aspect of the present application provides a functional food for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0096] The Leuconostoc mesenteroides CJLM119 strain and culture were as described above.
[0097] The fermented product of the present application may be one that has been fermented with at least one selected from the strains of the present application or cultures thereof at 32°C to 42°C for 10 hours to 30 hours, as described above.
[0098] The fermented product of the present application may be a fermented composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source, as described above.
[0099] The fermented product of the present application may be a fermented composition containing 5 to 9% by weight of garlic based on the total weight of the composition, as described above.
[0100] The fermented product of the present application may be a product obtained by fermenting a composition further comprising at least one selected from a carbon source or a salt, as described above.
[0101] The fermentation product of the present application may contain at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom, as described above.
[0102] In this application, "functional food" means food manufactured and processed using raw materials or ingredients that have functional properties that are beneficial to the human body according to the Functional Food Act (Article 3, Paragraph 1), and "functionality" means regulating nutrients to the structure and function of the human body or providing beneficial effects for health purposes, such as physiological actions (Article 3, Paragraph 2).
[0103] The functional food of the present application may be in the form of a food additive.
[0104] When the functional food of the present application is used as a food additive, the functional food may be added as a composition as it is, or may be used together with other foods or food ingredients, and may be used appropriately in a conventional manner. The active ingredient is used appropriately depending on the purpose of use (prevention or improvement). In general, when producing a food or beverage, the functional food composition of the present application is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, for long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
[0105] The functional food may further include food additives, as described above.
[0106] Yet another aspect of the present application provides an immune enhancing feed composition comprising Leuconostoc mesenteroides CJLM119 strain or a fermentation product of a culture thereof.
[0107] Yet another aspect of the present application provides a feed composition for improving intestinal health, comprising Leuconostoc mesenteroides CJLM119 strain or a fermentation product of a culture thereof.
[0108] The Leuconostoc mesenteroides CJLM119 strain and culture were as described above.
[0109] The fermented product of the present application may be one that has been fermented with at least one selected from the strains of the present application or cultures thereof at 32°C to 42°C for 10 hours to 30 hours, as described above.
[0110] The fermented product of the present application may be a fermented composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source, as described above.
[0111] The fermented product of the present application may be a fermented composition containing 5 to 9% by weight of garlic based on the total weight of the composition, as described above.
[0112] The fermented product of the present application may be a product obtained by fermenting a composition further comprising at least one selected from a carbon source or a salt, as described above.
[0113] The fermentation product of the present application may contain at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom, as described above.
[0114] The feed composition of the present application may be in the form of a feed additive composition other than a feed composition.
[0115] When the composition of the present application is produced as a feed additive, the composition may be a highly concentrated liquid of 20 to 90%, or may be produced in the form of a powder or granules. The feed additive may further contain one or more of organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, etc., phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), etc., polyphenols, catechin, α-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, etc. When produced as a feed, the composition may be formulated in the form of a normal feed, and may also contain normal feed ingredients.
[0116] The feed and feed additives may further include grains such as crushed or crushed wheat, oats, barley, corn and rice, vegetable protein feeds such as feeds based on rapeseed, beans and sunflower, animal protein feeds such as blood meal, meat meal, bone meal and fish meal, sugar and dairy products such as various types of milk powder and whey powder, and may further include nutritional supplements, digestive and absorption promoters, growth promoters, etc.
[0117] The feed additives may be administered to animals alone or in combination with other feed additives in an edible carrier. The feed additives may also be readily administered to animals as top dressings or by mixing them directly with the animal feed, or in oral dosage forms separate from the feed. When the feed additives are administered separately from the animal feed, they may be combined with pharma- ceutically acceptable edible carriers to produce immediate or sustained release dosage forms, as is well known in the art. Such edible carriers may be solid or liquid, such as corn starch, lactose, sucrose, bean flakes, peanut oil, olive oil, sesame oil, and propylene glycol. When a solid carrier is used, the feed additive may be a tablet, capsule, powder, lozenge, cough lozenge, or top dressing in microdispersed form. When a liquid carrier is used, the feed additive may be in the form of a gelatin soft capsule, syrup, suspension, emulsion, or solution.
[0118] The feed and feed additives may also contain auxiliary agents, such as preservatives, stabilizers, wetting or emulsifying agents, solution enhancers, etc. The feed additives may be added to the animal feed by immersion, spraying or mixing.
[0119] The feed or feed additive of the present application may be applied to many animal diets, including mammals, poultry and fish.
[0120] The mammals include pigs, cows, horses, sheep, rabbits, goats, rodents, and laboratory rodents such as mice, hamsters, and guinea pigs, as well as pets (e.g., dogs and cats). The poultry include chickens, turkeys, ducks, geese, pheasants, and quails. The fish include carp, crucian carp, and trout, but are not limited to these.
[0121] Yet another aspect of the present application provides a method for producing an immune enhancing composition, comprising fermenting a composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0122] Yet another aspect of the present application provides a method for producing a composition for improving gut health, comprising fermenting a composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0123] The Leuconostoc mesenteroides CJLM119 strain and culture were as described above.
[0124] The composition produced by the method of the present application may be a fermentation product.
[0125] The fermented product of the present application may be one that has been fermented with at least one selected from the strains of the present application or cultures thereof at 32°C to 42°C for 10 hours to 30 hours, as described above.
[0126] The fermented product of the present application may be a fermented composition containing 5 to 9% by weight of garlic based on the total weight of the composition, as described above.
[0127] The fermented product of the present application may be a product obtained by fermenting a composition further comprising at least one selected from a carbon source or a salt, as described above.
[0128] The fermentation product of the present application may contain at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom, as described above.
[0129] Yet another aspect of the present application provides a method for enhancing the immune enhancing effect of a composition comprising fermenting the composition with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0130] Yet another aspect of the present application provides a method for enhancing the gut health improving effect of a composition, comprising fermenting the composition with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0131] The Leuconostoc mesenteroides CJLM119 strain, culture, immune enhancement, and gut health improvement have been described above. EXAMPLES
[0132] The present application will be described in more detail below with reference to examples. However, these examples are merely preferred embodiments illustrating the present application, and the present application is not limited thereto. In addition, technical matters not described in this specification can be fully understood and easily implemented by skilled artisans in the technical field of the present application or a similar technical field. In addition, many papers and patent documents are referenced throughout this specification, and citations thereof are provided. The disclosures of the cited papers and patent documents are incorporated herein in their entirety by reference, thereby more clearly explaining the state of the art to which the present application belongs and the contents of the present application.
[0133] Production Example: Production of Fermented Composition First, the raw materials except for the strain were mixed as shown in Table 1 to prepare each composition. When preparing the composition, 7% by weight of garlic, 1.2% by weight of ginger, 2% by weight of chili powder, 3% by weight of carbon source (crystalline fructose), 1.5% by weight of salt, and 1.2% by weight of seasoning (TasteNrich (registered trademark), TNR, CJ CheilJedang) as a nitrogen source were added and then mixed. Next, 2% by weight of Leuconostoc mesenteroides CJLM119 strain (Accession No. KCTC13043BP, Patent Document 1) or Leuconostoc mesenteroides KCTC3505 was added, water was added until it reached 100% by weight, mixed, and then cultured at 30°C for 20 hours to ferment, thereby preparing the fermentation compositions of Preparation Examples 1 to 4 and Comparative Examples 1 to 3. After fermentation, the number of Leuconostoc mesenteroides CJLM119 strains in each fermentation composition was 2 × 10 8 cfu / mL.
[0134] The supernatant of the fermented composition was obtained by centrifuging the fermented composition at 13,000 rpm for 5 minutes and removing the bacterial cells from the supernatant with a 0.45 μm syringe filter. The Leuconostoc mesenteroides strain in the fermented composition was consistently 10 8 It was predominant at CFU / mL or higher.
[0135] [Table 1] EXAMPLES
[0136] Confirmation of cytotoxicity of fermented compositions The presence or absence of cytotoxicity in each fermentation composition was confirmed by WST-1 assay (Roche). The WST-1 assay was performed using a cell proliferation reagent WST-1 assay kit (Roche, USA) according to the manufacturer's instructions.
[0137] Specifically, J774A.1, a mouse macrophage line, was used as the animal cell line provided by the Korean Cell Line Bank (KCLB). The cells were cultured in DMEM (Gibco, USA) medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, penicillin G (100 IU / mL), and streptomycin (100 mg / mL) at 5% CO. 2 The cells were cultured at 37°C in the presence of 5 × 10 4 The cells were dispensed into a 96-well plate (Corning, USA) at a volume of 150 μL per well, and cultured for about 3 hours until a complete monolayer was formed, and then used in the experiment.
[0138] 1-1. Cytotoxicity of fermented compositions in each material The fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2 were diluted with antibiotic-free DMEM medium and dispensed in 100 μL portions into a 96-well plate. As control groups, antibiotic-free DMEM medium (negative control group) or antibiotic-free DMEM medium (positive control group) containing 1 μg / mL LPS (Lipopolysaccharide) was dispensed in 100 μL portions into a 96-well plate. The J774A.1 cells in each fermentation composition or control group were 3.3×10 5 The 96-well plate was incubated at 5% CO 2 The cells were incubated at 37°C for 24 hours in the presence of
[0139] After incubation, the cell supernatant was removed, WST-1 was diluted to 10% with DMEM, and 100 μL was dispensed into each well. 2 The cells were incubated in the presence of 100 mM NaCl at 37° C. for 1 hour, and then the absorbance was measured at 500 nm using a Spectrophotometer (BioTek, USA).
[0140] As a result, it was confirmed that the cell viability was increased in all of the cells treated with the fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2 compared to the negative control group, and that there was no cytotoxicity (FIG. 1).
[0141] 1-2. Cytotoxicity of fermented composition The fermentation composition of Production Example 4 was diluted with antibiotic-free DMEM medium to determine that the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 5 × 10 6 cfu / mL (Fermentation Composition A), 10 6 cfu / mL (Fermentation Composition B) and 5 × 10 5 cfu / mL (fermentation composition C), which was then dispensed in 100 μL portions into a 96-well plate. The supernatants of fermentation compositions A to C were diluted to the same dilution ratio with antibiotic-free DMEM, which was then dispensed in 100 μL portions into a 96-well plate. As controls, antibiotic-free DMEM medium (negative control group) or antibiotic-free DMEM medium supplemented with 1 μg / mL LPS (positive control group) was dispensed in 100 μL portions into a 96-well plate. The J774A.1 cells in each fermentation composition, its supernatant, or control group were 3.3 × 10 5 The 96-well plate was incubated at 5% CO 2 The mixture was cultured in the presence of the above-mentioned extract for 24 hours at 37° C. After the culture, the absorbance was measured at 500 nm using a spectrophotometer in the same manner as in Example 1-1.
[0142] As a result, Leuconostoc mesenteroides CJLM119 strain was 5 × 10 6 cfu / mL (Fermentation Composition A), 10 6 cfu / mL (Fermentation Composition B) and 5 × 10 5 It was confirmed that cell viability was maintained and no cytotoxicity was observed in cells treated with the fermentation composition contained at cfu / mL (Fermentation Composition C) and its supernatant (Figure 2).
[0143] 1-3. Cytotoxicity of fermented composition in each fermentation strain The fermentation composition of Production Example 4 was diluted with antibiotic-free DMEM medium, and the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was found to be 1.25 × 10 6 cfu / mL, 2.5×10 6cfu / mL, 5.0×10 6 cfu / mL and 6.25 × 10 6 The resultant was diluted with DMEM medium without antibiotics to obtain a fermentation composition with a concentration of 1.25 × 10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25 × 10 6 cfu / mL, and then 100 μL of each was dispensed into a 96-well plate. As controls, 100 μL of DMEM medium without antibiotics (negative control group) or DMEM medium without antibiotics containing 1 μg / mL LPS (positive control group) was dispensed into a 96-well plate. The J774A.1 cells in each fermentation composition or control group were 3.3 × 10 5 The 96-well plate was incubated at 5% CO 2 The mixture was cultured in the presence of the above-mentioned extract for 24 hours at 37° C. After the culture, the absorbance was measured at 500 nm using a spectrophotometer in the same manner as in Example 1-1.
[0144] As a result, Leuconostoc mesenteroides CJLM119 strain or KCTC3505 strain was 1.25 × 10 6 cfu / mL and 6.25 × 10 6 It was confirmed that all cells treated with the fermentation composition contained in cfu / mL showed increased cell viability and no cytotoxicity compared to the negative control group (Figure 3).
[0145] In addition, Leuconostoc mesenteroides CJLM119 or KCTC3505 strains were 1.25 × 10 6 cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 It was confirmed that all cells treated with the fermentation composition contained in cfu / mL showed increased cell viability and no cytotoxicity compared to the negative control group (Figure 4). EXAMPLES
[0146] Confirmation of immune enhancing effect of fermented composition In order to evaluate the immune enhancing effect of the fermentation compositions of Production Examples 1 to 4, the secretion ability of Th1 type pro-inflammatory cytokines TNF-α (Tumor necrosis factor-α) and IL-6 (Interleukin-6) was confirmed by ELISA assay.
[0147] 2-1. Immuno-enhancing effects of fermented compositions of each ingredient The fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2 were diluted with antibiotic-free DMEM medium and dispensed in 100 μL portions into a 96-well plate. As control groups, antibiotic-free DMEM medium (negative control group) or antibiotic-free DMEM medium containing 1 μg / mL LPS (positive control group) was dispensed in 100 μL portions into a 96-well plate. The J774A.1 cells in each fermentation composition or control group were 3.3×10 5 The 96-well plate was incubated at 5% CO 2 The cells were incubated at 37°C for 24 hours in the presence of
[0148] After the incubation, the culture medium was centrifuged at 1,400 rpm for 10 min to obtain the cell supernatant from which the J774A.1 and Leuconostoc mesenteroides bacteria were removed. ELISA assays were performed using Duoset ELISA ancillary reagent kit 2 (R&D systems, cat DY008, USA). Mouse TNF-α DuoSet ELISA kit (R&D systems, cat number DY 406-05, USA) containing TNF-α antibody and biotinylated secondary antibody, and Mouse IL-6 DuoSet ELISA kit (R&D systems, cat number DY 410-05, USA) containing IL-6 antibody and biotinylated secondary antibody were used according to the manufacturer's guidelines. ELISA plates were coated with TNF-α capture antibody (R&D systems, cat number 840143) and IL-6 capture antibody (R&D systems, cat number 840171) for 24 hours at room temperature, and then 100 μL of cell supernatant and TNF-α standard solution (R&D systems, cat number 840145) or IL-6 standard solution (R&D systems, cat number 840173) were diluted with reaction diluent (R&D systems, cat number DY995), added to the plate in 100 μL each, and incubated at room temperature for 2 hours. After that, the culture medium was removed, and secondary antibodies, biotinylated TNF-α antibody (R&D systems, cat number 840144) and IL-6 antibody (R&D systems, cat number 840172), were added, and coated at room temperature for 2 hours. The color reaction was induced by streptavidin-conjugated horseradish peroxidase (R&D systems, cat number 893975) and its substrate TMB (tetramethylbenzidine, R&D systems, cat number DY999). After the color reaction had progressed, 50 μL of stop solution (2N H 2 SO 4) was added to each well. Here, the color changed from blue to yellow due to a color reaction. After the color reaction was completed, the absorbance was measured at 470 nm (corrected value 540 nm) using a spectrophotometer.
[0149] As a result, in all of the cells treated with the fermentation compositions of Production Examples 1 to 3 and Comparative Examples 1 and 2, the expression of TNF-α ( FIG. 5 ) and IL-6 ( FIG. 6 ) was significantly increased compared to the negative control group ( *** p<0.001).
[0150] In particular, it was confirmed that the fermented composition of Preparation Example 1, in which a garlic-containing composition was fermented with Leuconostoc mesenteroides CJLM119 strain, exhibited excellent immune-enhancing effects, with significantly increased expression of TNF-α and IL-6 compared to other fermented compositions, and the expression of TNF-α and IL-6 was significantly increased compared to Comparative Example 2, in which a garlic-containing composition was not fermented with Leuconostoc mesenteroides CJLM119 strain.
[0151] Specifically, as shown in FIG. 5, in the cells treated in Comparative Example 2 in which the garlic-containing composition was not fermented with the Leuconostoc mesenteroides CJLM119 strain, IL-6 expression was higher than that of the other fermented compositions and the control group. However, in the cells treated in Production Example 1 in which the garlic-containing composition was fermented with the Leuconostoc mesenteroides CJLM119 strain, IL-6 expression increased by about two-fold, confirming that the fermented composition fermented using the Leuconostoc mesenteroides CJLM119 strain has a significantly superior immune-enhancing effect.
[0152] 2-2. Immune enhancing effect of fermented composition The fermentation composition of Production Example 4 was diluted with antibiotic-free DMEM medium to determine that the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 5 × 10 6 cfu / mL, 10 6 cfu / mL and 5×10 5cfu / mL, which were then dispensed in 100 μL portions into 96-well plates. The J774A.1 cells in each fermentation composition were 3.3 × 10 5 The 96-well plate was incubated at 5% CO 2 The mixture was cultured in the presence of 0.1% by weight at 37° C. for 24 hours. After the culture, when the color reaction was completed, the absorbance was measured at 470 nm (corrected value: 540 nm) using a spectrophotometer in the same manner as in Example 2-1.
[0153] As a result, Leuconostoc mesenteroides CJLM119 strain was 5 × 10 6 cfu / mL, 10 6 cfu / mL and 5×10 5 In cells treated with the fermentation composition containing cfu / mL, the expression of TNF-α ( FIG. 7 ) and IL-6 ( FIG. 8 ) was significantly increased or was equivalent to the negative control group ( *** p<0.001, ** p<0.01).
[0154] In particular, Leuconostoc mesenteroides CJLM119 strain was 5 × 10 6 It was confirmed that fermented composition A, containing cfu / mL, significantly increased the expression of TNF-α and IL-6 compared to the other fermented compositions, and exhibited excellent immune enhancing effects.
[0155] 2-3. Immuno-enhancing effect of fermented compositions from each fermentation strain The fermentation composition of Production Example 4 was diluted with antibiotic-free DMEM medium, and the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was found to be 1.25 × 10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25 × 10 6 The resultant was diluted with DMEM medium without antibiotics to obtain a fermentation composition with a concentration of 1.25 × 106 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25 × 10 6 cfu / mL, and then 100 μL of each was dispensed into a 96-well plate. As controls, 100 μL of DMEM medium without antibiotics (negative control group) or DMEM medium without antibiotics containing 1 μg / mL LPS (positive control group) was dispensed into a 96-well plate. The J774A.1 cells in each fermentation composition or control group were 3.3 × 10 5 The 96-well plate was incubated at 5% CO 2 The mixture was cultured in the presence of 0.1% by weight for 24 hours at 37° C. After the culture, when the color reaction was completed, the absorbance was measured at 470 nm (corrected value: 540 nm) using a spectrophotometer in the same manner as in Example 2-1.
[0156] As a result, Leuconostoc mesenteroides CJLM119 strain was 1.25 × 10 6 cfu / mL and 6.25 × 10 6 In all cells treated with the fermentation composition at cfu / mL, the expression of TNF-α (Figure 9) and IL-6 (Figure 11) was significantly increased compared to the negative control group ( *** p<0.001). Leuconostoc mesenteroides KCTC3505 strain was 1.25 × 10 6 cfu / mL and 6.25 × 10 6 In cells treated with the fermentation composition containing LM119 fermentation composition (1.25 × 10 6 cfu / mL, 6.25×10 6 cfu / mL), and IL-6 expression was significantly lower than that of the LM119 fermentation composition (1.25 × 10 6 cfu / mL) (Figures 9 and 11, ## p<0.01, # p<0.05).
[0157] In addition, Leuconostoc mesenteroides CJLM119 strain was 1.25 × 10 6 cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 In all cells treated with the fermentation composition at cfu / mL, the expression of TNF-α (FIG. 10) and IL-6 (FIG. 12) was significantly increased compared to the negative control group ( *** p<0.001, ** p<0.01, * p<0.05). Leuconostoc mesenteroides KCTC3505 strain was 2.5 × 10 6 In cells treated with the fermentation composition containing LM119 fermentation composition at 2.5 × 10 cfu / mL, the expression of TNF-α was significantly increased compared to that of the LM119 fermentation composition (2.5 × 10 6 cfu / mL), and IL-6 expression was significantly lower than that of the LM119 fermentation composition (2.5 × 10 6 cfu / mL and 5.0×10 6 cfu / mL) (Figures 10 and 12, *** p<0.001, ** p<0.01, * p<0.05). EXAMPLES
[0158] Confirmation of the harmful bacteria growth inhibition effect of fermentation composition in each material To confirm the effect of the fermentation composition of Preparation Example 4 in inhibiting the growth of harmful bacteria, Escherichia coli and Staphylococcus aureus, pathogenic microorganisms known to cause food poisoning, were inoculated into BHI (Brain heart infusion) broth medium (BD DIFCO) and then cultured at 37°C for 24 hours to obtain seed bacteria. BHI broth medium was prepared by diluting the fermentation composition of Preparation Example 4 to concentrations of 0, 25, 40, and 50% (v / v). 200 μl of each of the diluted media was dispensed into a 96-well plate, and 1 x 10 E. coli and S. aureus strains were each inoculated. 6The 96-well plate was cultured at 37° C. for 24 hours. After the culture, the OD 600 The OD value was measured in the medium containing 0% of the fermentation composition. 600 values and OD in diluted medium containing 25, 40 and 50% (v / v) of the fermentation composition. 600 The OD of each diluted medium not inoculated with a bacterial strain was calculated by comparing the values and confirming the inhibition ratio (%) of harmful bacteria at each concentration of the fermentation composition. 600 The value was set to Blank.
[0159]
number
[0160] As a result, the fermentation composition of Production Example 1 exhibited a strong growth inhibition rate of 90% or more against food poisoning bacteria E. coli and S. aureus at all concentrations (FIG. 13).
[0161] From the above description, a person skilled in the art to which the present application pertains will understand that the present application can be implemented in other specific forms without changing its technical ideas or essential features. It should be understood that the above examples are merely illustrative and not limiting. This application should be interpreted as including all modifications or alterations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification.
[0162] JPEG2024541607000004.jpg195145
Claims
1. A fermentation composition comprising at least one selected from the group consisting of Leuconostoc mesenteroides CJLM119 strain and cultures thereof.
2. An immune enhancing food composition comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
3. A food composition for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
4. The food composition according to claim 2 or 3, wherein the fermented product is a fermented composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source.
5. The food composition according to claim 2 or 3, wherein the fermented product is a fermented composition containing 5 to 9% by weight of garlic based on the total weight of the composition.
6. The food composition according to claim 2 or 3, which increases the expression of TNF-α or IL-6.
7. The food composition according to claim 2 or 3, which inhibits the growth of harmful bacteria.
8. 8. The food composition according to claim 7, wherein the harmful bacteria is at least one selected from the group consisting of Escherichia sp., Staphylococcus sp., Salmonella sp., Shigella sp., Klebsiella sp., Enterobacteriaceae sp., Pseudomonas sp., Moraxella sp., Helicobacter sp., Stenotrophomonas sp., Listeria sp. and Vibrio sp.
9. The food composition according to claim 2 or 3, wherein the fermented product is fermented at 32°C to 42°C for 10 hours to 30 hours.
10. The food composition according to claim 2 or 3, wherein the fermented product is a fermented composition further comprising at least one selected from a carbon source and a salt.
11. The food composition according to claim 2 or 3, wherein the fermented product comprises at least one selected from a culture of Leuconostoc mesenteroides CJLM119 strain, a disruptant thereof, an extract thereof, or a component derived therefrom.
12. The food composition according to claim 2 or 3, wherein the fermented product is a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof, or a fermented product obtained by further fermenting the fermented product.
13. A functional food for enhancing immunity, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
14. A functional food for improving intestinal health, comprising a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
15. The functional food according to claim 12 or 13, wherein the fermented product is a fermented composition comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source.
16. The functional food according to claim 12 or 13, wherein the fermented product is a fermented composition containing 5 to 9% by weight of garlic based on the total weight of the composition.
17. The functional food according to claim 12 or 13, wherein the fermented product is a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof, or a fermented product obtained by further fermenting the fermented product.
18. 13. A method for enhancing the immune enhancing effect of a composition, comprising the step of fermenting the composition with Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
19. 13. A method for enhancing the gut health improving effect of a composition, comprising the step of fermenting the composition with Leuconostoc mesenteroides strain CJLM119 or a culture thereof.
20. 20. The method of claim 18 or 19, comprising at least one selected from the group consisting of garlic, chili powder and a nitrogen source.
21. 20. The method of claim 18 or 19, wherein the composition is a food composition.
Citation Information
Patent Citations
Method for producing condensed and matured kimchi fermentation liquid, condensed and matured kimchi fermentation liquid, condensed and matured kimchi fermentation seasoning agent, kimchi and kimchi block
JP2013106610A
Functional fermented food with high lycopene content
JP2021502103A
Lactic acid bacterium separated from kimchii and uses thereof
KR101194798B1
Method for manufacturing samgyetang for retort and samgyetang for retort manufactured with this
KR102671787B1
Lactic acid bacteria having pro-inflammatory characteristics
WO2009007515A1
